The efficacy of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion_Chinese Journal of Ocular Fundus Diseases

Authors：

SongShuang ,  YuXiaobing , DaiHong

Department of Ophthalmology, Beijing Hospital, Beijing 100730, China;

Corresponding author：

YuXiaobing, Email: yuxiaobing@sina.com

Keywords：

Retinal vein occlusion/therapy; Angiogenesis inhibitors/therapeutic use; Antibodies; monoclonal/therapeutic use; Laser coagulation

DOI：

10.3760/cma.j.issn.1005-1015.2015.01.006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the efficacy and safety of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion (BRVO) during one year period. Methods The data of 31 eyes from 31 consecutive patients with macular edema secondary to BRVO during one year follow-up visit were retrospectively analyzed. Mean best corrected visual acuity (BCVA) logMAR was (0.74±0.36) and mean central retinal thickness (CRT) was (484.48±164.81)μm at baseline. All patients received standardized clinical comprehensive examinations including vision, intraocular pressure and optical coherence tomography for diagnosis before treatment. All patients received intravitreal injections of 0.5 mg ranibizumab (0.05 ml) at first visit. The continue PRN treatment were based on the visual acuity changes and the optical coherence tomography findings. Eyes received combined triamcinolone acetonide 0.05 ml (40 mg/ml) and ranibizumab for macular edema recurrence after two injections of ranibizumab and received laser photocoagulation during 10-14 days after third injections of ranibizumab. Mean injection of ranibizumab was 3.52±2.01, 15 eyes with triamcinolone acetonide (0.84±1.21), 21 eyes with laser photocoagulation (0.97±0.95) and 12 eyes with three treatment. Compared the visual acuities and CRTs of the first and the last visits by statistical analysis. Results Mean visual acuity improved significantly to 0.42±0.33 logMAR (t=6.611, P=0.000). Mean improvement of visual acuity was 2.90±3.07 lines. A gain of three or more logarithmic lines was evaluated in 20/31 eyes (64.52%) at the last visit. Mean CRT was (326.19±117.80)μm (t=4.514, P=0.000).Mean reduction of CRT was (333.58±134.17)μm. A decrease of 100μm of CRT was evaluated in 17/31 eyes (54.84%). No severe ocular and systematic side effect was found. Conclusion The efficacy and safety of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to BRVO were assured.

Citation： SongShuang, YuXiaobing, DaiHong. The efficacy of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion. Chinese Journal of Ocular Fundus Diseases, 2015, 31(1): 18-21. doi: 10.3760/cma.j.issn.1005-1015.2015.01.006 Copy

1.	Angulo Bocco MC, Glacet-Bernard A, Zourdani A, et al. Intravitreous injection:retrospective study on 2028 injections and their side effects[J].J Fr Ophtalmol, 2008, 31(7):693-698.
2.	The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion[J]. Am J Ophthalmol, 1984, 98(3):271-282.
3.	Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide[J]. Eye, 2005, 19(1):65-71.
4.	喻晓兵, 师自安, 戴虹, 等.曲安奈德玻璃体腔注射治疗视网膜分支静脉阻塞继发黄斑水肿[J].中国实用眼科杂志, 2006, 24(10):1043-1045.
5.	Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion:six-month primary end point results of a phaseⅢstudy[J]. Ophthalmology, 2010, 117(6):1102-1112.
6.	Rouvas A, Petrou P, Ntouraki A, et al.Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema:nine-month results of a prospective study[J]. Retina, 2010, 30(6):893-902.
7.	Azad SV, Salman A, Mahajan D, et al.Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion[J]. Middle East Afr J Ophthalmol, 2014, 21(4):296-301.
8.	Pece A, Isola V, Piermarocchi S, et al. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion:1-year follow-up[J]. Br J Ophthalmol, 2011, 95(1):56-68.
9.	Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema[J]. Ophthalmologica, 2010, 224(1):8-15.
10.	Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions:implication of VEGF as a critical stimulator[J]. Mol Ther, 2008, 16 (4):791-799.
11.	Noma H, Mimura T, Eguchi S.Association of inflammatory factors with macular edema in branch retinal vein occlusion[J]. JAMA Ophthalmol, 2013, 131(2):160-165.
12.	Gerding H, Monés J, Tadayoni R, et al. Ranibizumab in retinal vein occlusion:treatment recommendations by an expert panel[J].Br J Ophthalmol, 2014, 98(7):E305041.http://bjo.bmj.com/cgi/pmidlookup?view=long&pmid=25075121.
13.	张雪岩, 李艳波, 周黎纹, 等.玻璃体腔注射雷珠单抗联合激光光凝治疗BRVO合并黄斑水肿[J].国际眼科杂志, 2014, 14(4):747-749.
14.	张聪, 许贺, 徐丽.玻璃体腔注射Ranibizumab联合激光治疗BRVO继发黄斑水肿的观察[J].国际眼科杂志, 2014, 14(8):1399-1402.

1. Angulo Bocco MC, Glacet-Bernard A, Zourdani A, et al. Intravitreous injection:retrospective study on 2028 injections and their side effects[J].J Fr Ophtalmol, 2008, 31(7):693-698.
2. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion[J]. Am J Ophthalmol, 1984, 98(3):271-282.
3. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide[J]. Eye, 2005, 19(1):65-71.
4. 喻晓兵, 师自安, 戴虹, 等.曲安奈德玻璃体腔注射治疗视网膜分支静脉阻塞继发黄斑水肿[J].中国实用眼科杂志, 2006, 24(10):1043-1045.
5. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion:six-month primary end point results of a phaseⅢstudy[J]. Ophthalmology, 2010, 117(6):1102-1112.
6. Rouvas A, Petrou P, Ntouraki A, et al.Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema:nine-month results of a prospective study[J]. Retina, 2010, 30(6):893-902.
7. Azad SV, Salman A, Mahajan D, et al.Comparative evaluation between ranibizumab combined with laser and bevacizumab combined with laser versus laser alone for macular oedema secondary to branch retinal vein occlusion[J]. Middle East Afr J Ophthalmol, 2014, 21(4):296-301.
8. Pece A, Isola V, Piermarocchi S, et al. Efficacy and safety of anti-vascular endothelial growth factor (VEGF) therapy with intravitreal ranibizumab (Lucentis) for naive retinal vein occlusion:1-year follow-up[J]. Br J Ophthalmol, 2011, 95(1):56-68.
9. Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema[J]. Ophthalmologica, 2010, 224(1):8-15.
10. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions:implication of VEGF as a critical stimulator[J]. Mol Ther, 2008, 16 (4):791-799.
11. Noma H, Mimura T, Eguchi S.Association of inflammatory factors with macular edema in branch retinal vein occlusion[J]. JAMA Ophthalmol, 2013, 131(2):160-165.
12. Gerding H, Monés J, Tadayoni R, et al. Ranibizumab in retinal vein occlusion:treatment recommendations by an expert panel[J].Br J Ophthalmol, 2014, 98(7):E305041.http://bjo.bmj.com/cgi/pmidlookup?view=long&pmid=25075121.
13. 张雪岩, 李艳波, 周黎纹, 等.玻璃体腔注射雷珠单抗联合激光光凝治疗BRVO合并黄斑水肿[J].国际眼科杂志, 2014, 14(4):747-749.
14. 张聪, 许贺, 徐丽.玻璃体腔注射Ranibizumab联合激光治疗BRVO继发黄斑水肿的观察[J].国际眼科杂志, 2014, 14(8):1399-1402.

Chinese Journal of Ocular Fundus Diseases

The efficacy of intravitreal ranibizumab and (or) triamcinolone combined with laser photocoagulation for macular edema secondary to branch retinal vein occlusion

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content